Biotechnology Law Report

Papers
(The TQCC of Biotechnology Law Report is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
In Juno v. Kite the Federal Circuit Strikes Down Patent Directed Towards Pioneering Innovation in CAR T-Cell Therapy3
Selected Developments in Biotechnology Law and the Biotechnology Industry3
Legal and Ethical Challenges in the Construction of China's Biobanks3
Selected Developments in Biotechnology Law and the Biotechnology Industry3
Legislative Moves on Biosecurity in China2
Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines2
Introduction on Biosafety Law of the People's Republic of China and Linkage Thereof with International and Domestic Regulations2
GlaxoSmithKline v. Teva: Holding a Generic Liable for an Artificial Act of Inducement2
Sanofi-Aventis Deutschland GmbH v. Mylan Pharms. Inc.1
Moo-re Gene-edited Animals Get Regulatory Clearance: U.S. FDA Approves Genetically Engineered Cattle for Human Consumption1
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part II1
Ferring B.V. v. Allergan, Inc. United States Court of Appeals of the Federal Circuit, 2020 980 F.3d 8411
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Eli Lilly & Co. v. Apotex, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1328, 2020 WL 7490251 (Non-precedential)1
HIPAA, HIPPA, or HIPPO: What Really Is the Heath Insurance Portability and Accountability Act?1
Novartis Pharms. Corp. v. Accord Healthcare, Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies1
Recent Developments at the Intersection of Pharma, Patents, and Antitrust Law1
A Look at the Current Status of the CRISPR Patent Interferences Involving Broad Institute, University of California and University of Vienna, ToolGen, and Sigma-Aldrich1
Amgen Inc. v. Sanofi, Aventisub LLC United States Court of Appeals of the Federal Circuit, 2021 987 F.3d 10801
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Recent Developments in FDA Regulatory Exclusivities1
In re Huping Hu United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2104, 2021 WL 1016437 (non-precedential)1
United Therapeutics Corp. v. Liquidia Techs., Inc.1
A 2023 Review of Legislation Aimed at Increasing Generic and Biosimilar Competition1
Vectura Ltd. v. Glaxosmithkline LLC. United States Court of Appeals of the Federal Circuit, 2020 981 F.3d 10301
The Legislative Paradigm of China's Biosafety Law and Its Positive Significance for the SARS-CoV-2 Prevention and Control1
Navigating Cross-Border Challenges In Biobanking: Analysing Eu Legislation, ECJ Case Law, and the Role of Private International Law1
SawStop Holding LLC v. Vidal United States Court of Appeals of the Federal Circuit, 2022 48 F.4th 13551
Observation on China's Performance in the Global Supply Chain of COVID-19 Medicine1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
In re Couvaras1
Incorrect Translation Causing a Claim to Be Indefinite Under 35 U.S.C. § 112—A Case Study of IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc.1
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I1
Horizon Pharma, Inc. v. Dr. Reddy's Labs. Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-1607, 2021 WL 48428 (Non-precedential)1
CareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 13711
Observation on the R&D Effectiveness and Application of China's Novel Coronavirus Vaccine1
Allgenesis Biotherapeutics Inc. v. Cloudbreak Therapeutics, LLC1
Bio-Rad Labs., Inc. v. 10X Genomics Inc. United States Court of Appeals of the Federal Circuit, 2020 967 F.3d 13531
Biogen MA Inc. v. EMD Serono, Inc. United States Court of Appeals of the Federal Circuit, 2020 976 F.3d 13261
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Bayer Healthcare LLC v. Baxalta Inc. United States Court of Appeals of the Federal Circuit, 2021 989 F.3d 9641
Selected Developments in Biotechnology Law and the Biotechnology Industry1
The Federal Circuit Continues to Grapple with the Question of Patent Eligibility for Diagnostic Methods1
Regulation of Biomedical Research: Global and Indian Perspective1
Par Pharm., Inc. v. Eagle Pharms., Inc.1
A Review of Patent Regimes on Health Biotechnology Innovation in India1
14-Day Limit of Human Embryo Research: Moral Issues in the Patent Law in China1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Juno Therapeutics, Inc. v. Kite Pharma, Inc. United States Court of Appeals of the Federal Circuit, 202110 F.4th 13301
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Observation on the Admission Situation of the Anti-Coronavirus Drug “Remdesivir” in China1
AstraZeneca AB v. Mylan Pharms. Inc.1
Medytox, Inc. v. Galderma S.A.1
Univ. of Massachusetts v. L'Oreal S.A.1
The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRIPSR1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Par Pharm., Inc. v. Hospira, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1273, 2020 WL 6846347 (Non-precedential)1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
XY, LLC v. Trans Ova Genetics, LC United States Court of Appeals of the Federal Circuit, 2020 968 F.3d 13231
Selected Developments in Biotechnology Law and the Biotechnology Industry1
0.083546161651611